Actuate Therapeutics announced that its Phase 2 data on elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC) have been selected for an oral presentation and a poster presentation at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California. The oral presentation, titled “Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab‑paclitaxel versus gemcitabine/nab‑paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma,” is scheduled for January 9 2026 at 4:15 PM PST. The poster presentation, titled “Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK‑3 inhibitor elraglusib and gemcitabine/nab‑paclitaxel in the 1801 Part 3B Phase 2 study,” will be shown on January 9 2026 from 11:30 AM to 1:00 PM and again from 5:00 PM to 6:00 PM PST.
Elraglusib is a glycogen synthase kinase‑3β (GSK‑3β) inhibitor that has demonstrated promising activity in the Phase 2 mPDAC trial. The study reported a doubling of the one‑year survival rate and an improvement in median overall survival when elraglusib was combined with standard gemcitabine/nab‑paclitaxel chemotherapy. These results suggest that elraglusib may enhance the efficacy of existing first‑line therapy for a disease with limited treatment options.
Metastatic pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with a 5‑year survival rate below 10 %. The standard first‑line regimen is gemcitabine plus nab‑paclitaxel, yet overall outcomes remain poor. Actuate’s data address this unmet need, and the company has received FDA orphan drug designation for pancreatic cancer, positioning elraglusib for a potentially accelerated regulatory pathway.
Presenting the data at ASCO GI provides a platform for scientific scrutiny, potential collaboration opportunities, and increased visibility among oncology clinicians and investors. The event is a key milestone in Actuate’s development program, reinforcing investor confidence and supporting the company’s strategy to advance elraglusib toward regulatory approval.
Actuate previously presented topline results from the same Phase 2 study at the ASCO Annual Meeting on May 31 2025. The upcoming ASCO GI Symposium will run from January 8‑10 2026 in San Francisco, offering a high‑profile venue for the company’s clinical data.
The selection of Actuate’s Phase 2 pancreatic cancer data for oral and poster presentations at ASCO GI 2026 marks a significant step forward in the company’s pipeline, positioning elraglusib for further development and potential regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.